Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial

BACKGROUND: The role of remdesivir in the treatment of hospitalized patients with COVID-19 remains ill-defined. We conducted a cost-effectiveness analysis alongside the Canadian Treatments for COVID-19 (CATCO) open-label, randomized clinical trial evaluating remdesivir. METHODS: Patients with COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Vincent I., Fowler, Robert, Pinto, Ruxandra, Tremblay, Alain, Borgia, Sergio, Carrier, François M., Cheng, Matthew P., Conly, John, Costiniuk, Cecilia T., Daley, Peter, Duan, Erick, Durand, Madeleine, Fontela, Patricia S., Farjou, George, Fralick, Mike, Geagea, Anna, Grant, Jennifer, Keynan, Yoav, Khwaja, Kosar, Lee, Nelson, Lee, Todd C., Lim, Rachel, O’Neil, Conar R., Papenburg, Jesse, Semret, Makeda, Silverman, Michael, Sligl, Wendy, Somayaji, Ranjani, Tan, Darrell H.S., Tsang, Jennifer L.Y., Weatherald, Jason, Yansouni, Cedric Philippe, Zarychanski, Ryan, Murthy, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477473/
https://www.ncbi.nlm.nih.gov/pubmed/36199248
http://dx.doi.org/10.9778/cmajo.20220077

Ejemplares similares

Ejemplares similares